Alpha DNA Investment Management’s Elevance Health ELV Stock Holding History

Alpha DNA Investment Management’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,655	Closed	-$1.72M	–	64
2024 Q4	$1.72M	Buy	4,655 +645	+16%	+$270K	0.65%	35
2024 Q3	$2.09M	Buy	4,010 +232	+6%	+$124K	0.78%	22
2024 Q2	$2.05M	Sell	3,778 -220	-6%	-$116K	0.8%	25
2024 Q1	$2.07M	Buy	3,998 +2,179	+120%	+$1.08M	0.77%	21
2023 Q4	$858K	Sell	1,819 -2,919	-62%	-$1.35M	0.33%	57
2023 Q3	$2.06M	Buy	4,738 +28	+0.6%	+$12.7K	0.84%	16
2023 Q2	$2.09M	Buy	4,710 +262	+6%	+$121K	0.7%	21
2023 Q1	$2.05M	Buy	4,448 +1,256	+39%	+$598K	0.6%	16
2022 Q4	$1.64M	Buy	3,192 +590	+23%	+$300K	0.58%	26
2022 Q3	$1.18M	Buy	+2,602	New	+$1.25M	0.98%	23

Other funds holding ELV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Alpha DNA Investment Management's ELV Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of Elevance Health (ELV) in Q1 2025, closing a stake of 4,655 shares — an estimated $1.72M sold.

Alpha DNA Investment Management first reported a position in ELV in Q3 2022 and held it in 10 quarters. The position peaked at $2.09M in Q2 2023. 1,660 funds tracked by Wall St. Rank hold ELV as of Q1 2025.

Alpha DNA Investment Management reported no remaining Elevance Health position as of Q1 2025 after selling out during the quarter.
Alpha DNA Investment Management sold 4,655 Elevance Health shares in Q1 2025, an estimated $1.72M.
Alpha DNA Investment Management first reported a position in Elevance Health in Q3 2022 and held it in 10 quarters.
Alpha DNA Investment Management's Elevance Health position peaked at $2.09M in Q2 2023.
1,660 funds tracked by Wall St. Rank held Elevance Health as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.